# Mpex Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mpex-pharmaceuticals

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.mpexpharma.com
- Total disclosed funding: $75M
- Latest round: Series D (Feb 5, 2009)
- Investors on record: 6

## About

Mpex Pharmaceuticals Inc. is a San Diego-based biopharmaceutical company focused on developing innovative therapeutic solutions aimed at addressing unmet medical needs in various health domains.Founded in 2001, Mpex Pharmaceuticals Inc. specializes in developing novel therapies for infectious diseases. The company has undergone significant developments in its business strategy over the years. Mpex Pharmaceuticals was previously a subsidiary under Axcan Pharma Inc., which announced its intent to acquire the company in April 2011. The firm has secured a total of USD 27.50 mn in funding through multiple rounds, with its latest round being a Series D, finalized with investors including Aberdare Ventures and others, achieving a current valuation of USD 78.02 mn.Mpex Pharmaceuticals offers a portfolio of innovative therapeutic solutions tailored for the healthcare sector. Its flagship product integrates advanced technology to enhance user experience and improve operational efficiencies, particularly in the management of infectious diseases. The company serves a diverse client base, including healthcare institutions, and ensures product distribution across major markets in North America, Europe, and Asia.The revenue model of Mpex Pharmaceuticals is based on subscription-based services and direct sales to healthcare providers. Clients typically engage via long-term agreements that offer access to proprietary treatments and technologies. Though specific pricing details are confidential, the structure is designed to accommodate various client needs, fostering sustained relationships through value-driven offerings.Mpex Pharmaceuticals is focused on expanding its product offerings with new therapeutic developments planned for launch in 2023. The company aims to penetrate additional markets in Europe and Asia by the end of 2024. The recent funding from the Series D round will support these initiatives, ensuring resources are allocated towards research and development as well as strategic market entry efforts.

## Funding rounds

- Series D, Feb 5, 2009, $28M — Adams Street Partners, HBM Partners, Aberdare Ventures, RiverVest Ventures Partners, SV Health Investors
- Series C, Dec 27, 2007, $15M — Adams Street Partners
- Series B, Aug 11, 2005, $32M — Adams Street Partners, HBM Partners, Aberdare Ventures, SV Health Investors, Western States Investment Group

## Investors

- Adams Street Partners (https://capitalatlas.ai/funds/adams-street-partners) — Series B, Series C, Series D
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B, Series D
- Aberdare Ventures (https://capitalatlas.ai/funds/aberdare-ventures) — Series B, Series D
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series B, Series D
- Western States Investment Group (https://capitalatlas.ai/funds/western-states-investment-group) — Series B
- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Series D